Autor: |
Shakila, Meshkat, Roger C, Ho, Bing, Cao, Kayla M, Teopiz, Joshua D, Rosenblat, Taeho Greg, Rhee, Joshua D, Di Vincenzo, Felicia, Ceban, Muhammad Youshay, Jawad, Roger S, McIntyre |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Journal of Affective Disorders. 323:598-606 |
ISSN: |
0165-0327 |
Popis: |
Ketamine is a NMDA receptor antagonist that has a rapid acting antidepressant effect with high efficacy in treatment-resistant patients. Ketamine is a beneficial antidepressant for many individuals with depression, but not all of the patients respond, and some even exhibit symptom deterioration. The discovery of repeatable and mechanistically relevant biomarkers would address a major gap in treatment response prediction. Numerous potential peripheral biomarkers have been reported, but their current utility is unclear. We conducted an umbrella review to evaluate the biomarkers of ketamine's antidepressant effect in individuals with depression. PubMed and copus were searched using terms appropriate to each area of research, from their inception until July 2022. Five systematic reviews and meta analyses including 108 studies with 4912 participants were included. Blood-based and neuroimaging biomarkers were investigated. The results of this review indicate that ketamine can produce an anti-inflammatory effect and decrease at least one inflammatory marker following administration. Data from neuroimaging studies demonstrated that the cingulate cortex is the key locus of ketamine's action. The majority of the blood-based, neuroimaging, and neurophysiological investigations reviewed herein indicate ketamine induced normalization of major depressive disorder pathogenesis via synaptic plasticity and functional connectivity. Currently, no biomarker/biosignature is sufficiently validated for clinical utility, but several are promising. Now that ketamine is more widely available, biomarker discovery and replication should be attempted in larger, real-world populations. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|